Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial.
Saved in:
| Title: | Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. |
|---|---|
| Authors: | Seufferlein, Thomas1 (AUTHOR) thomas.seufferlein@uniklinik-ulm.de, Lausser, Ludwig2,3 (AUTHOR), Stein, Alexander4 (AUTHOR), Arnold, Dirk5 (AUTHOR), Prager, Gerald6 (AUTHOR), Kasper-Virchow, Stefan7 (AUTHOR), Niedermeier, Michael8 (AUTHOR), Müller, Lothar9 (AUTHOR), Kubicka, Stefan10 (AUTHOR), König, Alexander11 (AUTHOR), Büchner-Steudel, Petra12 (AUTHOR), Wille, Kai13 (AUTHOR), Berger, Andreas W.1 (AUTHOR), Kestler, Angelika M. R.1 (AUTHOR), Kraus, Johann M.2 (AUTHOR), Werle, Silke D.2 (AUTHOR), Perkhofer, Lukas1 (AUTHOR), Ettrich, Thomas J.1 (AUTHOR), Kestler, Hans A.2 (AUTHOR) thomas.seufferlein@uniklinik-ulm.de |
| Source: | PLoS ONE. 6/14/2024, Vol. 19 Issue 6, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
